# SphingoTec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sphingotec

- Industry: Biotechnology
- Headquarters: Hennigsdorf, Germany
- Website: www.sphingotec.com/
- Total disclosed funding: $28M
- Latest round: Series C (Jul 25, 2024)
- Investors on record: 14

## About

SphingoTec GmbH, based in Germany, specializes in developing bio-analytical solutions, offering innovative in vitro diagnostic products focused on proprietary blood-based protein biomarkers for critical and acute care settings.Founded in 2013 and headquartered in Hennigsdorf, Germany, SphingoTec GmbH focuses on the development of biomarker diagnostic solutions. The company has notably secured Series C funding amounting to EUR 5 million on July 25, 2024, led by Think.Health Ventures with numerous other investors participating. The total amount raised to date is EUR 5 million, with a current valuation of EUR 8.646 million.SphingoTec GmbH specializes in the development and marketing of innovative in vitro diagnostic (IVD) solutions centered around proprietary blood-based protein biomarkers. The company's core product offerings include CE IVD microtiter plate assays for biomarkers such as penKid, which assesses kidney function, and bio-ADM, which evaluates endothelial function. These products target critical and acute care settings, specifically addressing conditions like acute kidney injury, sepsis, and acute heart failure. SphingoTec's solutions are designed to fill diagnostic gaps in intensive care units, enabling early intervention and personalized medicine to improve patient outcomes. The company's client base comprises international academic and non-academic medical centers, global pharmaceutical companies, and laboratories, with products marketed primarily in Europe, North America, and select regions in Asia.SphingoTec generates revenue through the sale of its proprietary biomarker assays, primarily transacted through partnerships with medical institutions and laboratories that utilize its products for clinical diagnostics. The transaction structure typically involves direct sales to hospitals and laboratories, where customers procure the CE IVD microtiter plate assays for routine testing and patient management. Revenue streams are bolstered by collaborations with global IVD firms and pharmaceutical companies, leveraging the company's innovations in biomarker diagnostics. Specific pricing structures for products are not disclosed, but the assays operate under a model where healthcare providers purchase kits for clinical use, facilitating ongoing relationships with end users in critical and acute care environments.SphingoTec GmbH plans to utilize the EUR 5 million raised in Series C funding to accelerate market expansion and financial progress. The company is focused on launching new products and expanding its offerings into additional markets, with specific targets in Europe and North America. While exact release dates for upcoming products have not been disclosed, the funding will support these initiatives aimed at enhancing its diagnostic solutions in critical healthcare settings.

## Funding rounds

- Series C, Jul 25, 2024, $5.4M — Wellington Partners, HBM Partners, NRW Bank, Brandenburg Kapital, TerVia Invest, Think.Health Ventures, V2 Holding AG, Green Protect Consulting & Invest UG, Biotec CCI AG, MS Beteiligungsgesellschaft mbH, GV Beteiligungsgesellschaft mbH, NeuroPep GmbH
- Series B, Mar 14, 2023, $1.6M — Wellington Partners, HBM Partners, NRW Bank, TerVia Invest
- Series B, Jul 19, 2022, $7.8M — Wellington Partners, HBM Partners, NRW Bank, Brandenburg Kapital, TerVia Invest
- Series A, Dec 5, 2019, $7.6M — NRW Bank, Brandenburg Kapital, Plain Vanilla Investments, Deutsche Biotech Innovativ AG
- Series A, Jun 27, 2019, $5.1M — HBM Partners

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A, Series B, Series C
- NRW Bank — Series A, Series B, Series C
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series A, Series B, Series C
- Plain Vanilla Investments (https://capitalatlas.ai/funds/plain-vanilla-investments) — Series A
- Deutsche Biotech Innovativ AG — Series A
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series B, Series C
- TerVia Invest — Series B, Series C
- Think.Health Ventures (https://capitalatlas.ai/funds/think-health-ventures) — Series C
- V2 Holding AG — Series C
- Green Protect Consulting & Invest UG — Series C
- Biotec CCI AG — Series C
- MS Beteiligungsgesellschaft mbH — Series C
- GV Beteiligungsgesellschaft mbH — Series C
- NeuroPep GmbH — Series C